Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400908 | 0.81 | DDB1 (0.54) | MEN1KMT2AMGLLALDH1A1SMN1; SMN2 | |
| SCHEMBL6399716 | 0.76 | MEN1 (0.59) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6404679 | 0.73 | RAB9A (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL30157756 | 0.73 | MEN1 (0.63) | MEN1KMT2AMGLLALDH1A1 | |
| SCHEMBL3770108 | 0.73 | MEN1 (0.63) | MEN1KMT2AMGLLALDH1A1 | |
| SCHEMBL15025454 | 0.72 | MEN1 (0.68) | MEN1KMT2AMGLLSCN9ASCN10A | |
| SCHEMBL6404669 | 0.72 | DRD2 (0.48) | MEN1KMT2AMGLLALDH1A1GRM5 | |
| SCHEMBL15108903 | 0.71 | MEN1 (0.61) | MEN1KMT2AMGLLALDH1A1 | |
| SCHEMBL31607797 | 0.70 | CRBN (0.66) | MEN1KMT2AMGLLSMN1; SMN2 | |
| SCHEMBL25575700 | 0.70 | CRBN (0.66) | MEN1KMT2AMGLLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | MEN1 1510/4885KMT2A 673/4885MGLL 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.